Leukine (sargramostim)
Leukine (sargramostim) is an FDA approved medical countermeasure to treat those acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS).
Availability: Commercially Available
| Manufacturer |
| Partner Therapeutics, Inc. |
| Product Name |
| Leukine (sargramostim) |
| Detection Category |
| Radiological/Nuclear |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| Leukine (sargramostim) is an FDA approved medical countermeasure to treat those acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 9 |
| Market Entry Date |
| 2018 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Transportability |
| Pocket Size |
| Operating Time |
| Immediate post-exposure use |
| Standards Met |
| FDA |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |